Jennerex Biotherapeutics is a private, clinical-stage biotherapeutics company focused on the development and commercialization of targeted oncolytic immunotherapies for solid tumors. Our lead product Pexa-Vec (JX-594) is currently in a randomized Phase 2b clinical trial for hepatocellular carcinoma (HCC) and Phase 2 clinical development for colorectal cancer (CRC) and kidney cancer (RCC).